Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSL 787

Next Previous
Drug Profile

CSL 787

Alternative Names: CSL-787; Nebulised immunoglobulin - CSL Behring

Latest Information Update: 07 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Class Immunoglobulins; Serum globulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Bronchiectasis

Most Recent Events

  • 02 Jul 2025 CSL Behring plans a phase II trial for Bronchiectasis (Inhalation) in July 2025 (NCT07048262)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Bronchiectasis(Prevention) in United Kingdom (Inhalation, Aerosol)
  • 27 Jul 2023 Phase-I clinical trials in Bronchiectasis (Prevention) in Germany (Inhalation) (NCT04643587)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top